drugset / Trial / NCT01581710

Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.

NCT01581710

RandomizedCrossoverQuadruple-blindPrevention

Summary

This study aims to identify markers to prove rapid improvement of lung function, airway inflammation and bronchodilator response after 2-week LTRA administration.

Timeline

Start
2012-05
Primary completion
2015-09
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Montelukast Other / unclassified 4 mg
Comparator Montelukast Other / unclassified 5 mg

Indications